7 Cepheid Analyst Ratings, Earnings, Dividends and Insider Trades | $CPHD | NASDAQ:CPHD | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Cepheid Company Profile (NASDAQ:CPHD) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Cepheid (NASDAQ:CPHD) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Sell Rating(s), 8 Hold Rating(s), 6 Buy Rating(s)Consensus Rating:Hold (Score: 2.33)Consensus Price Target: $48.73 10.81% downside) Analysts' Ratings History for Cepheid (NASDAQ:CPHD) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare1/31/2014Jefferies GroupBoost Price Target$36.00 -> $43.00View 1/31/2014Raymond JamesBoost Price Target$50.00 -> $57.00View 1/31/2014OppenheimerBoost Price Target$43.00 -> $54.00View 1/31/2014UBS AGBoost Price TargetBuy$48.00 -> $55.00View 1/31/2014ISI GroupBoost Price Target$38.00 -> $39.00View 1/31/2014Cowen and CompanyBoost Price Target$52.00 -> $53.00View 1/31/2014Citigroup Inc.Boost Price Target$48.00 -> $53.00View 1/31/2014Canaccord GenuityBoost Price TargetBuy$50.00 -> $55.00View 1/31/2014MizuhoBoost Price TargetBuy$50.00 -> $65.00View 1/7/2014JPMorgan Chase & Co.DowngradeOverweight -> NeutralView 12/19/2013Needham & CompanyInitiated CoverageHoldView 12/18/2013JMP SecuritiesInitiated CoverageMarket PerformView 12/13/2013UBS AGBoost Price TargetBuy$44.00 -> $48.00View 11/22/2013Raymond JamesBoost Price TargetBuy$43.00 -> $50.00View 11/20/2013WedbushSet Price TargetOutperform$42.00 -> $47.00View 11/14/2013ZacksReiterated RatingNeutral -> Neutral$44.00View 11/3/2013UBS AGReiterated RatingBuy$44.00View 10/28/2013Cowen and CompanyBoost Price TargetOutperform$42.00 -> $44.00View 10/18/2013WedbushReiterated RatingBuy$42.00View 10/18/2013UBS AGBoost Price TargetBuy$40.00 -> $44.00View 10/18/2013ISI GroupLower Price TargetSell$34.00 -> $33.50View 10/18/2013Canaccord GenuityBoost Price TargetBuy$45.00 -> $50.00View 10/18/2013MizuhoBoost Price TargetBuy$42.00 -> $50.00View 10/10/2013SunTrustInitiated CoverageNeutralView 10/3/2013WedbushBoost Price TargetOutperform$37.00 -> $42.00View 10/1/2013Bank of AmericaDowngradeBuy -> NeutralView 10/1/2013Bank of AmericaDowngradeBuy -> Neutral$39.00 -> $41.00View 9/5/2013UBS AGReiterated RatingBuy$40.00View 9/5/2013Cowen and CompanyBoost Price TargetOutperform$39.00 -> $42.00View 8/19/2013WedbushReiterated RatingBuy$37.00View 8/19/2013UBS AGBoost Price TargetBuy$39.00 -> $40.00View 8/6/2013ZacksDowngradeNeutral -> Underperform$33.00View 7/19/2013WedbushLower Price TargetOutperform$40.00 -> $37.00View 7/19/2013Raymond JamesLower Price TargetOutperform$43.00 -> $42.00View 7/19/2013Jefferies GroupLower Price TargetHold$38.00 -> $36.00View 7/19/2013UBS AGLower Price TargetBuy$42.00 -> $39.00View 7/19/2013Craig HallumDowngradeHold -> SellView 7/19/2013Piper JaffrayUpgradeNeutral -> Overweight$37.00 -> $43.00View 6/26/2013OppenheimerInitiated CoverageOutperform$41.00View 6/3/2013Craig HallumDowngradeBuy -> Hold$42.00 -> $35.00View 5/31/2013Jefferies GroupDowngradeBuy -> Hold$38.00View 5/9/2013ZacksReiterated RatingNeutral -> Neutral$41.00View 4/19/2013Raymond JamesBoost Price TargetOutperform$40.00 -> $43.00View 4/19/2013OppenheimerBoost Price TargetOutperform$39.00 -> $41.00View 4/19/2013MizuhoBoost Price TargetBuy$37.00 -> $42.00View 4/19/2013Credit SuisseBoost Price TargetOutperform$40.00 -> $45.00View 4/19/2013Cantor FitzgeraldBoost Price TargetHold$38.00 -> $40.00View 4/19/2013UBS AGBoost Price TargetBuy$40.00 -> $42.00View 4/19/2013MizuhoBoost Price TargetBuy$37.00 -> $42.00View 4/18/2013Leerink SwannBoost Price TargetMarket Perform$36.00 -> $38.00View 4/18/2013Citigroup Inc.Initiated CoverageNeutral$40.00View 2/5/2013ZacksReiterated RatingNeutral -> Neutral$38.00View 1/28/2013ZacksReiterated RatingNeutral -> Neutral$40.00View 1/25/2013UBS AGLower Price TargetBuy$43.00 -> $40.00View 1/25/2013Cowen and CompanyReiterated RatingOutperformView 1/22/2013Robert W. BairdReiterated RatingOutperform$45.00View 1/11/2013ZacksReiterated RatingNeutral -> Neutral$37.00View 1/4/2013Piper JaffrayDowngradeOverweight -> Neutral$42.00 -> $34.00View 12/28/2012Cantor FitzgeraldReiterated RatingHold$38.00View 12/28/2012Canaccord GenuityReiterated RatingBuy$50.00View 12/28/2012OppenheimerReiterated RatingOutperform$43.00View 12/28/2012William BlairReiterated RatingOutperformView 12/17/2012Bank of AmericaInitiated CoverageBuy$40.00View 12/6/2012Goldman SachsDowngradeNeutralView 11/19/2012Goldman SachsDowngradeBuy -> Neutral$42.00 -> $32.00View 11/16/2012MizuhoInitiated CoverageNeutral -> Buy$37.00View 11/6/2012ZacksReiterated RatingNeutral -> Neutral$33.00View 11/5/2012Craig HallumInitiated CoverageBuy$42.00View 10/19/2012ISI GroupLower Price TargetSell$30.50 -> $29.00View 10/2/2012Cowen and CompanyInitiated CoverageOutperformView 9/28/2012Canaccord GenuityReiterated RatingBuy$50.00View 9/28/2012Cantor FitzgeraldReiterated RatingHoldView 9/28/2012Goldman SachsReiterated RatingBuy$46.00View 9/28/2012Credit SuisseLower Price TargetOutperform$41.00View 9/28/2012UBS AGReiterated RatingBuy$43.00View 9/27/2012Piper JaffrayReiterated RatingOverweight$32.00View 9/27/2012OppenheimerReiterated RatingOutperform$43.00View 9/27/2012ISI GroupLower Price TargetSell$35.00 -> $32.50View 9/26/2012JPMorgan Chase & Co.Initiated CoverageOverweight$47.00View 8/29/2012Cantor FitzgeraldInitiated CoverageHold$40.00View 8/17/2012ZacksReiterated RatingNeutral -> Neutral$38.00View 8/7/2012Piper JaffrayReiterated RatingOverweight$42.00View 7/23/2012ZacksReiterated RatingNeutral -> Neutral$38.00View 7/20/2012UBS AGReiterated RatingBuyView 7/20/2012WedbushLower Price Target$45.00 -> $42.00View 7/20/2012Credit SuisseLower Price TargetOutperform$45.00View 7/20/2012StephensDowngradeEqual Weight -> UnderweightView 7/12/2012Canaccord GenuityReiterated RatingBuyView 7/9/2012ISI GroupInitiated CoverageUnderweight$47.00View 5/24/2012Canaccord GenuityReiterated RatingBuyView 5/15/2012UBS AGUpgradeNeutral -> Buy$45.00View 5/14/2012GARP ResearchDowngradeBuy -> NeutralView 5/11/2012ZacksDowngradeOutperform -> Neutral$39.00View 4/20/2012UBS AGReiterated RatingNeutral$45.00 -> $44.00View 4/20/2012Credit SuisseLower Price TargetOutperform$45.00View 4/20/2012Canaccord GenuityReiterated RatingBuyView 4/5/2012ZacksUpgradeNeutral -> Outperform$49.00View (Data available from 3/8/2012 forward) Earnings History for Cepheid (NASDAQ:CPHD)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare1/31/2014Q413($0.11)($0.15)$102.17 million$113.30 millionViewN/AView 10/17/2013Q313($0.11)($0.20)$93.70 million$100.10 millionViewN/AView 7/18/2013Q2 2013$0.04$0.02$92.57 million$96.00 millionViewN/AView 4/18/2013Q1 2013$0.10$0.11$89.12 million$91.90 millionViewN/AView 1/24/2013Q4 2012$0.11$0.20$92.87 million$92.40 millionViewN/AView 10/18/2012($0.07)($0.32)ViewN/AView 7/19/2012$0.11$0.11ViewN/AView 4/19/2012($0.01)($0.08)ViewN/AView 1/26/2012($0.02)($0.03)ViewN/AView 10/20/2011$0.02$0.03ViewN/AView 7/21/2011($0.01)$0.03ViewN/AView 4/20/2011($0.01)$0.01ViewN/AView 1/27/2011($0.02)$0.02ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Cepheid (NASDAQ:CPHD)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Cepheid (NASDAQ:CPHD)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare1/31/2014Andrew MillerCFOSell63,375$53.10$3,365,212.50View 1/31/2014John BishopCEOSell150,000$50.67$7,600,500.00View 1/31/2014Joseph SmithEVPSell50,000$51.15$2,557,500.00View 1/3/2014Kerry FlomEVPSell6,357$45.66$290,260.62View 1/2/2014Andrew MillerCFOSell2,437$45.92$111,907.04View 12/23/2013Kerry FlomEVPSell10,000$46.51$465,100.00View 10/30/2013David H PersingVPSell5,000$41.35$206,750.00View 10/29/2013Kerry FlomEVPSell2,660$40.50$107,730.00View 10/24/2013Thomas L GutshallDirectorSell3,000$40.07$120,210.00View 10/18/2013David H PersingVPSell20,000$40.59$811,800.00View 9/24/2013Thomas GutshallDirectorSell3,000$38.97$116,910.00View 9/18/2013David PersingVPSell5,000$39.34$196,700.00View 9/16/2013David PersingVPSell5,000$38.95$194,750.00View 9/6/2013David H PersingVPSell20,000$37.99$759,800.00View 8/30/2013David PersingVPSell5,129$36.62$187,823.98View 8/26/2013Thomas GutshallDirectorSell3,000$36.38$109,140.00View 8/21/2013Robert EastonDirectorSell7,500$35.01$262,575.00View 7/24/2013Thomas L GutshallDirectorSell3,000$34.18$102,540.00View 6/24/2013Thomas L GutshallDirectorSell3,000$32.91$98,730.00View 5/28/2013Andrew MillerCFOSell22,468$38.51$865,242.68View 5/24/2013Thomas L GutshallDirectorSell3,000$37.90$113,700.00View 5/13/2013Kerry FlomEVPSell6,832$39.76$271,640.32View 3/25/2013Thomas L GutshallDirectorSell3,000$38.28$114,840.00View 2/4/2013Joseph H SmithEVPSell38,400$36.20$1,390,080.00View 12/24/2012Thomas L GutshallDirectorSell3,000$33.06$99,180.00View 11/26/2012Thomas L GutshallDirectorSell7,778$31.94$248,429.32View (Data available from 1/1/2013 forward) About Cepheid Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market. The Company's systems enable rapid, sophisticated molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's two principal systems are the GeneXpert and SmartCycler. The GeneXpert system, its primary offering in the Clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for a broad range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Headlines: (2/10) Cepheid Announces Closing Of $345 Million Of 1.25% Convertible Senior Notes Due 2021 (2/25) Cepheid (CPHD) Has Taken Out The Highs Of The Morning (2/21) Updated Research Report on Cepheid (2/6) Cepheid to Webcast Upcoming Financial Presentations (2/11) Cepheid Down to Strong Sell (2/25) Tuesday's ETF Movers: FBT, GDXJ (2/14) Cepheid Inc (CPHD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: CPHD CUSIP: 15670R10 Key Metrics: Previous Close: $54.3950 Day Moving Average: $51.1232200 Day Moving Average: $43.9003 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $3.728BCurrent Quarter EPS Consensus Estimate: $-0.24 EPS Additional Links: View CPHD on Google FinanceView CPHD on Yahoo FinanceView CPHD's Company Profile on ReutersSearch for Cepheid on Google Cepheid (NASDAQ:CPHD) Chart for Saturday, March, 8, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.